Astellas Pharma Inc. Says Bid for CV Therapeutics, Inc. Its Best Offer

February 2, 2009 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

TOKYO, Feb 2 (Reuters) - Japanese drugmaker Astellas Pharma Inc said its $1 billion bid for U.S. biotechnology firm CV Therapeutics Inc is its best offer, ruling out the possibility of sweetening its bid for now.

Twitter
LinkedIn
Facebook
Email
Print

Mergers & acquisitions Asia

Astellas Pharma US, Inc.